Acquisition of EHT (Details) - USD ($) |
Jun. 30, 2022 |
May 11, 2022 |
Dec. 31, 2021 |
|---|---|---|---|
| Business Acquisition [Line Items] | |||
| Number of shares to be issued per acquiree share (in shares) | 1.95 | ||
| Deferred asset acquisition costs | $ 842,193 | $ 0 | |
| Emerald Health Therapeutics, Inc. | |||
| Business Acquisition [Line Items] | |||
| Number of shares to be issued per acquiree share (in shares) | 1.95 | ||
| Equity interest issued or issuable (in shares) | 416,270,585 | ||
| Dissent rights exercised, percent threshold | 5.00% |
| X | ||||||||||
- Definition Business Acquisition, Dissent Rights Exercised, Percent Threshold No definition available.
|
| X | ||||||||||
- Definition Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Entity Shares Issued Per Acquiree Share No definition available.
|
| X | ||||||||||
- Definition Number of shares of equity interests issued or issuable to acquire entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|